Morphometric Markers of the Effectiveness of Micropulse Cyclophotocoagulation

ConditionGlaucoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKazakh Eye Research Institute

About this trial

This prospective study aims to evaluate morphometric markers of treatment response following micropulse transscleral cyclophotocoagulation (MP-CPC) in patients with glaucoma. The study will assess changes in choroidal thickness and the choroidal vascularity index (CVI) measured by optical coherence tomography (OCT) before treatment, 3-7 days after the procedure, and 1 month postoperatively.

Intraocular pressure (IOP) will be measured at the same time points. The correlation between changes in choroidal thickness, the choroidal vascularity index (CVI) and IOP reduction will be analyzed. Additionally, the study seeks to determine the minimal baseline choroidal thickness associated with a clinically significant hypotensive effect after MP-CPC.

Eligibility criteria

Qualifiers

Decision to treat by MP-CPC Laser

Patients diagnosed with Glaucoma

Patients aged 18 years old and above

Glaucoma that is inadequately controlled on medical therapy

Disqualifiers

Patients age less than 18 years

Patients unable or unwilling to provide informed consent to participate in the study

Patients potentially unavailable for follow up visits

Patients with significant scleral thinning

Trial design

Treatments tested in this trial

  • MicroPulse transscleral cyclophotocoagulation
  • Conventional transscleral cyclophotocoagulation

Treatment groups

20 Participants
are divided into 2 treatment groups

Locations

1
Kazakh Eye Research Institute050012, Almaty Kazakhstan

Sponsors and collaborators

Kazakh Eye Research Institute

Lead sponsor